Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Calithera Biosci Com (CALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,703
  • Shares Outstanding, K 35,850
  • Annual Sales, $ 25,960 K
  • Annual Income, $ -27,830 K
  • 36-Month Beta 2.53
  • Price/Sales 6.42
  • Price/Cash Flow N/A
  • Price/Book 1.13

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +6.98%
on 07/11/18
5.55 -17.12%
on 06/21/18
-0.65 (-12.38%)
since 06/20/18
3-Month
4.30 +6.98%
on 07/11/18
6.83 -32.65%
on 05/10/18
-1.50 (-24.59%)
since 04/20/18
52-Week
4.30 +6.98%
on 07/11/18
18.35 -74.93%
on 10/18/17
-11.25 (-70.98%)
since 07/20/17

Most Recent Stories

More News
Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks

Stock Research Monitor: CALA, CARA, and CLDX

CARA : 19.06 (-1.04%)
CELG : 85.10 (-0.28%)
CLDX : 0.52 (+1.96%)
CALA : 4.60 (-1.08%)
CELGZ : 1.06 (+10.42%)
Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June

Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced today Susan M. Molineaux, Ph.D, founder, CEO and President...

CALA : 4.60 (-1.08%)
Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)

Phase 2 to Continue Enrolling Colorectal Cancer Patients with PIK3CA Mutation

CALA : 4.60 (-1.08%)
Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National Instruments with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Monster Beverage Corporation...

ZNGA : 4.25 (-0.70%)
MNST : 61.58 (+0.72%)
MRO : 20.48 (-0.29%)
CALA : 4.60 (-1.08%)
NATI : 43.00 (-1.24%)
INFN : 8.97 (-0.55%)
Technical Snapshots for These Biotech Stocks -- BioPharmX, bluebird bio, Calithera Biosciences, and Capricor Therapeutics

If you want a free Stock Review on BPMX, BLUE, CALA, and CAPR sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com draws investors' attention to BioPharmX Corp. (NYSE AMER:...

BLUE : 180.35 (+0.78%)
BPMX : 0.24 (+3.45%)
CALA : 4.60 (-1.08%)
CAPR : 1.30 (-2.99%)
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

LLY : 88.47 (-1.07%)
INCY : 69.20 (-1.30%)
IONS : 46.50 (+1.44%)
PRTA : 14.85 (-1.33%)
CALA : 4.60 (-1.08%)
AMGN : 190.49 (-0.66%)
BIIB : 358.71 (+0.17%)
Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018

Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that three abstracts describing CB-839, the Company's...

CALA : 4.60 (-1.08%)
Calithera's Kidney Cancer Candidate Gets Fast Track Status

Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

LGND : 231.88 (-0.28%)
EXEL : 21.29 (-0.23%)
CALA : 4.60 (-1.08%)
BMY : 56.71 (+0.30%)
Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma

Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA)...

CALA : 4.60 (-1.08%)
Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018

Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that preclinical research for its glutaminase...

CALA : 4.60 (-1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CALA with:

Business Summary

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase...

See More

Key Turning Points

2nd Resistance Point 4.93
1st Resistance Point 4.77
Last Price 4.60
1st Support Level 4.47
2nd Support Level 4.33

See More

52-Week High 18.35
Fibonacci 61.8% 12.98
Fibonacci 50% 11.33
Fibonacci 38.2% 9.67
Last Price 4.60
52-Week Low 4.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar